In Case You Missed It: Additional Abstracts of Interest From AACR

The 2025 American Association for Cancer Research (AACR) Annual Meeting featured forward-looking research studies, including the VICTORI trial on liquid biopsy, a phase I trial on a KRAS G12D inhibitor in NSCLC, a phase II trial on the use of a topical gel for skin toxicity from EGFR inhibitors, the KEYLYNK-007 trial on the combination of PARP and PD-1 inhibition, and the SKYSCRAPER-01 trial on tiragolumab plus atezolizumab in PD-L1–high NSCLC.